• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AOMORI OLYMPUS CO., LTD. SINGLE USE ASPIRATION NEEDLE NA-U200H

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AOMORI OLYMPUS CO., LTD. SINGLE USE ASPIRATION NEEDLE NA-U200H Back to Search Results
Model Number NA-U200H-8022S
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Abdominal Pain (1685); Hemorrhage/Blood Loss/Bleeding (1888); Hypoxia (1918); Pancreatitis (4481); Muscle Hypotonia (4531); Unspecified Tissue Injury (4559)
Date of Event 11/24/2022
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The suspect device has not been returned to olympus for evaluation.The investigation is in process.The literature article is attached for additional information.Once the investigation has been completed, a supplemental report will be submitted with device evaluation results.
 
Event or Problem Description
Olympus reviewed the following literature titled "factors affecting the learning curve in the endoscopic ultrasound-guided sampling of solid pancreatic lesions: a prospective study" literature summary background/aims: endosonography is associated with a long learning curve.We aimed to assess variables that may influence the diagnostic outcomes in endoscopic ultrasound-guided fine-needle aspiration/biopsy (eus-fna/b) of solid pancreatic tumors regarding the level of endoscopists' experience.Methods: consecutive patients undergoing eus-guided puncture of solid pancreatic tumors (eight endosonographers, including six trainees) were prospectively enrolled.An experienced endosonographer was defined as having performed at least 250 eus examinations, including 75 fna/bs.The final diagnosis was determined by cytopathology, histopathology, or clinical follow-up.Results: in total, 283 eus-fna/bs of solid pancreatic tumors (75.6% malignant) in 239 patients (median age 69 years, 57.6% males) were enrolled.Trainees performed 149/283 (52.7%) of the interventions.Accuracy and sensitivity for detecting malignancy were significantly higher in the expert group than in the trainee group (85.8% vs 73.2%, p=0.01 and 82.5% vs 68.4%, p=0.02).Solid lesions evaluated by an expert using fnb needles showed the best odds for a correct diagnosis (odds ratio, 3.07; 95% confidence interval, 1.15 to 8.23; p=0.02).More experienced endoscopists achieved better accuracy in sampling via the transduodenal approach (86.7% vs 68.5%, p<0.001), in the sampling of malignant lesions (82.5 vs 68.4, p=0.02), and in the sampling of lesions located in the pancreatic head (86.1 vs 69.1, p=0.02).In cases involving these factors, we observed a moderate improvement in the diagnostic accuracy after 40 attempts.Conclusions: transduodenal approach, pancreatic head lesions, and malignancy were recognized as the most important clinical factors affecting the learning curve in eus-fna/b of solid pancreatic lesions.Type of adverse events/number of patients event1: procedure-related adverse events (6 cases, including two major bleedings) - both were immediately stopped by endoscopic intervention.Event2: minor bleeding (32 cases) - overall, there was no need for a blood transfusion, and none of the patients presented as hemodynamically unstable.Event3: pancreatitis (1 case) - treated conservatively.Event4: severe abdominal pain (1 case) - treated conservatively.Event5: mucosal injury at the gastroesophageal junction (1 case) - treated conservatively.Event6: sedation-related complications (7 cases) - five with prolonged hypoxia and two with hypotonia.No intensive care admission was needed.Two complaints are required for this event, as there are two devices involved: (b)(6) is for the evis exera ii ultrasound gastrovideoscope (all events).(b)(6) is for the single use aspiration needle (all events).This report is for (b)(6).
 
Additional Manufacturer Narrative
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse events cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SINGLE USE ASPIRATION NEEDLE NA-U200H
Common Device Name
SINGLE USE ASPIRATION NEEDLE
Manufacturer (Section D)
AOMORI OLYMPUS CO., LTD.
2-248-1 okkonoki
kuroishi-shi, aomori 036-0 357
JA  036-0357
Manufacturer (Section G)
AOMORI OLYMPUS CO., LTD.
2-248-1 okkonoki
kuroishi-shi, aomori
Manufacturer Contact
todd brill
800 west park drive
westborough, MA 01581
5082077661
MDR Report Key18301195
Report Number9614641-2023-01870
Device Sequence Number3226176
Product Code FCG
UDI-Device Identifier04953170380525
UDI-Public04953170380525
Combination Product (Y/N)N
Initial Reporter CountryAU
PMA/510(K) Number
K180449
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other,Foreign,Study,Literature,Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 01/12/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model NumberNA-U200H-8022S
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 11/13/2023
Supplement Date Received by ManufacturerNot provided
Initial Report FDA Received Date12/11/2023
Supplement Report FDA Received Date01/12/2024
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Reuse
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient SexUnknown
-
-